A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

@article{Lai2004ADS,
  title={A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.},
  author={Ching Lung Lai and Seng Gee Lim and Nathaniel A. Brown and Xiao-jian Zhou and Deborah M Lloyd and Y M Lee and Man-fung Yuen and George C Chao and Maureen W Myers},
  journal={Hepatology},
  year={2004},
  volume={40 3},
  pages={719-26}
}
Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical safety profile. In this first clinical study of telbivudine… CONTINUE READING